Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,070 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Motzer RJ, et al. Among authors: thompson ja. J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1. J Clin Oncol. 2009. PMID: 19487381 Free PMC article. Corrected and republished. Clinical Trial.
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM. Motzer RJ, et al. Among authors: thompson ja. J Interferon Cytokine Res. 2001 Apr;21(4):257-63. doi: 10.1089/107999001750169934. J Interferon Cytokine Res. 2001. PMID: 11359657 Clinical Trial.
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.
Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A. Balch CM, et al. Among authors: thompson jf, thompson ja. J Clin Oncol. 2001 Aug 15;19(16):3622-34. doi: 10.1200/JCO.2001.19.16.3622. J Clin Oncol. 2001. PMID: 11504744
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.
Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Balch CM, et al. Among authors: thompson jf, thompson ja. J Clin Oncol. 2001 Aug 15;19(16):3635-48. doi: 10.1200/JCO.2001.19.16.3635. J Clin Oncol. 2001. PMID: 11504745 Review.
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.
Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE. Sondak VK, et al. Among authors: thompson ja. J Clin Oncol. 2002 Apr 15;20(8):2058-66. doi: 10.1200/JCO.2002.08.071. J Clin Oncol. 2002. PMID: 11956266 Clinical Trial.
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK; Southwest Oncology Group. Sosman JA, et al. Among authors: thompson ja. J Clin Oncol. 2002 Apr 15;20(8):2067-75. doi: 10.1200/JCO.2002.08.072. J Clin Oncol. 2002. PMID: 11956267 Clinical Trial.
1,070 results